Global Cancer Vaccines Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Technologies;

Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvent Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines.

By Types;

Preventive Cancer Vaccines, and Therapeutic Cancer Vaccines.

By Indication;

Cervical Cancer, Prostate Cancer, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn611942909 Published Date: June, 2024 Updated Date: July, 2024


Global Cancer Vaccines Market (USD Million), 2020 - 2030

In the year 2023, the Global Cancer Vaccines Market was valued at USD 8,130.22 million. The size of this market is expected to increase to USD 23,651.67 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 16.5%.

The global cancer vaccines market has been experiencing significant growth, driven by advancements in biotechnology and a heightened focus on personalized medicine. Cancer vaccines, designed to either prevent cancer from developing or to treat existing cancers, represent a groundbreaking approach in oncology. The growing incidence of various cancers worldwide, coupled with the limitations of traditional therapies, has underscored the need for innovative solutions such as vaccines. These vaccines work by stimulating the body’s immune system to recognize and attack cancer cells, offering a promising avenue for improving patient outcomes and survival rates.

The market is the increasing investment in research and development by both public and private sectors. Governments and healthcare organizations are allocating substantial funds to accelerate the development of effective cancer vaccines. Additionally, collaborations between pharmaceutical companies and research institutions are fostering an environment conducive to innovation. The approval and commercialization of several cancer vaccines, such as those for HPV and hepatitis B, which are linked to cervical and liver cancers respectively, have set a precedent, demonstrating the potential of vaccines in cancer prevention and treatment.

The market also faces challenges, including high development costs, stringent regulatory requirements, and the complexity of cancer biology which makes vaccine development inherently difficult. Despite these hurdles, the market is poised for growth, supported by technological advancements like next-generation sequencing and bioinformatics, which enhance the understanding of cancer genomics and immunology. As more clinical trials yield positive results and new vaccines gain regulatory approval, the global cancer vaccines market is expected to expand, offering hope for more effective cancer prevention and therapeutic options in the future.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Technologies
    2. Market Snapshot, By Types
    3. Market Snapshot, By Indication
    4. Market Snapshot, By Region
  4. Global Cancer Vaccines Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Cancer Incidence
        2. Rising Awareness
        3. Personalized Medicine
      2. Restraints
        1. High Development Costs
        2. Limited Access in Low-income Regions
        3. Variable Vaccine Efficacy
      3. Opportunities
        1. Collaborative Research
        2. Expansion of Preventive Vaccines
        3. Improved Healthcare Infrastructure
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Cancer Vaccines Market, By Technologies, 2020 - 2030 (USD Million)
      1. Dendritic Cells (DC) Cancer Vaccines
      2. Recombinant Cancer Vaccines
      3. Antigen/Adjuvent Cancer Vaccines
      4. Viral Vector & DNA Cancer Vaccines
    2. Global Cancer Vaccines Market, By Types, 2020 - 2030 (USD Million)
      1. Preventive Cancer Vaccines
      2. Therapeutic Cancer Vaccines
    3. Global Cancer Vaccines Market, By Indication, 2020 - 2030 (USD Million)
      1. Cervical Cancer
      2. Prostate Cancer
      3. Others
    4. Global Cancer Vaccines Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Advaxis Inc.
      2. Amgen Inc.
      3. Dynavax Technologies Corporation
      4. Generex Biotechnology Corporation
      5. GlaxoSmithKline plc (GSK)
      6. Immunocellular Therapeutics, Ltd
      7. Merck & Co., Inc.
      8. Sanpower Group CO. LTD. (DENDEREON CORPORATION)
      9. UbiVac
      10. Vaccinogen, Inc.
  7. Analyst Views
  8. Future Outlook of the Market